3PO as a selective inhibitor of 6-phosphofructo- 2-kinase/fructose-2,6-biphosphatase 3 in a375 human melanoma cells

27Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: The occurrence of BRAFV600E mutation causes an up-regulation of the B-raf kinase activity leading to the stabilization of hypoxia-inducible factor 1-alpha (HIF-1α) - the promoter of the 6-phosphofructo-2- kinase/fructose-2,6-biphosphatase 3 (PFKFB3) enzyme. The aim of the study was to examine the effect of the (2E)-3-(3- Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), as an inhibitor of PFKFB3, on human melanoma cells (A375) with endogenous BRAFV600E mutation. Materials and Methods: A375 cells were exposed to different concentrations of 3PO and the following tests were performed: Docking, cytotoxicity assay, immunocytochemistry staining glucose uptake, clonogenic assay, holotomography imaging, and flow cytometry. Results: Our studies revealed that 3PO presents a dose-dependent and time-independent cytotoxic effect and promotes apoptosis of A375 cells. Furthermore, the obtained data indicate that 3PO induces cell cycle arrest in G1/0 and glucose uptake reduction. Conclusion: Taking all together, our research demonstrated a here should be proapoptotic and antiproliferative effect of 3PO on A375 human melanoma cells.

Cite

CITATION STYLE

APA

Kotowski, K., Supplitt, S., Wiczew, D., Przystupski, D., Bartosik, W., Saczko, J., … Kulbacka, J. (2020). 3PO as a selective inhibitor of 6-phosphofructo- 2-kinase/fructose-2,6-biphosphatase 3 in a375 human melanoma cells. Anticancer Research, 40(5), 2613–2625. https://doi.org/10.21873/anticanres.14232

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free